Global Patent Index - EP 2145628 A1

EP 2145628 A1 20100120 - TREATMENT OF NEURODEGENERATIVE DISEASE THROUGH INTRACRANIAL DELIVERY OF SHORT INTERFERING RNA (SIRNA)

Title (en)

TREATMENT OF NEURODEGENERATIVE DISEASE THROUGH INTRACRANIAL DELIVERY OF SHORT INTERFERING RNA (SIRNA)

Title (de)

Behandlung neurodegenerativer Erkrankungen mittels intrakranialer Freisetzung von Small-Interfering-RNA (siRNA)

Title (fr)

Traitement de maladie neurodégénérative via l'administration intracrânienne de petit ARN interférent (sirna)

Publication

EP 2145628 A1 20100120 (EN)

Application

EP 09013626 A 20031126

Priority

  • EP 03790026 A 20031126
  • US 42938702 P 20021126
  • US 44461403 P 20030203

Abstract (en)

The present invention provides small interfering RNAs, short hairpin RNAs and vectors and pharmaceutical compositions comprising the siRNA and shRNAs. Methods for treating a neurodegenerative disorder, namely SCA-1 are also described. Particularly, the invention provides a small interfering RNA consisting of a first and second strand wherein said first strand is encoded by a DNA sequence comprising SEQ ID NO. 1 or SEQ ID NO. 2.

IPC 8 full level

A61K 31/713 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01); A61M 37/00 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01)

CPC (source: EP US)

A61K 9/0085 (2013.01 - EP US); A61K 31/713 (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); A61K 48/0075 (2013.01 - EP US); A61M 37/00 (2013.01 - EP US); A61P 25/14 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/28 (2018.01 - EP); C12N 15/111 (2013.01 - EP US); C12N 15/113 (2013.01 - EP US); C12N 2310/111 (2013.01 - EP US); C12N 2310/14 (2013.01 - EP US); C12N 2310/53 (2013.01 - EP US); C12N 2320/32 (2013.01 - EP US)

Citation (applicant)

  • WO 0116312 A2 20010308 - RIBOZYME PHARM INC [US], et al
  • WO 9950300 A1 19991007 - UNIV PENNSYLVANIA [US], et al
  • WO 2006000794 A1 20060105 - LIFESCAN SCOTLAND LTD [GB], et al
  • US 5735814 A 19980407 - ELSBERRY DENNIS D [US], et al
  • US 6042579 A 20000328 - ELSBERRY DENNIS D [US], et al
  • WO 9323569 A1 19931125 - RIBOZYME PHARM INC [US]
  • WO 9402595 A1 19940203 - RIBOZYME PHARM INC [US]
  • US 5624803 A 19970429 - NOONBERG SARAH B [US], et al
  • WO 9618736 A2 19960620 - RIBOZYME PHARM INC [US]
  • US 4683195 A 19870728 - MULLIS KARY B [US], et al
  • US 4683202 A 19870728 - MULLIS KARY B [US]
  • US 4800159 A 19890124 - MULLIS KARY B [US], et al
  • US 4965188 A 19901023 - MULLIS KARY B [US], et al
  • US 6093180 A 20000725 - ELSBERRY DENNIS D [US]
  • US 54044400 A 20000331
  • US 62575100 A 20000726
  • US 5814014 A 19980929 - ELSBERRY DENNIS D [US], et al
  • US 87269801 A 20010601
  • US 86464601 A 20010523
  • CLARK, H. ET AL., JOURNAL OFNEUROSCIENCE, vol. 17, 1997, pages 7385 - 7395
  • MATILLA, A. ET AL., JOURNAL OFNEUROSCIENCE, vol. 18, 1998, pages 5508 - 5516
  • KLEMENT, I. ET AL., CELL, vol. 95, 1998, pages 41 - 53
  • YAMAMOTO, A. ET AL., CELL, vol. 101, 2000, pages 57 - 66
  • CAPLEN ET AL., HUMAN MOLECULAR GENETICS, vol. 11, no. 2, 2002, pages 175 - 184
  • XIA; HAIBIN ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 1006 - 1010
  • IZANT; WEINTRAUB, SCIENCE, vol. 229, 1985, pages 345
  • MCGARRY; LINDQUIST, PROC. NATL. ACAD. SCI., USA, vol. 83, 1986, pages 399
  • SCANLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 10591 - 5
  • KASHANI- SABET ET AL., ANTISENSE RES. DEV., vol. 2, 1992, pages 3 - 15
  • DROPULIC ET AL., J VIROL., vol. 66, 1992, pages 1432 - 41
  • WEERASINGHE ET AL., J VIROL., vol. 65, 1991, pages 5531 - 4
  • OJWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10802 - 6
  • CHEN ET AL., NUCLEIC ACIDS RES., vol. 20, 1992, pages 4581 - 9
  • SARVER ET AL., SCIENCE, vol. 247, 1990, pages 1222 - 1225
  • THOMPSON ET AL., NUCLEIC ACIDS RES., vol. 23, 1995, pages 2259
  • GOOD ET AL., GENE THERAPY, vol. 4, 1997, pages 45
  • OHKAWA ET AL., NUCLEIC ACIDS SYMP. SER., vol. 27, 1992, pages 15 - 6
  • TAIRA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 5125 - 30
  • VENTURA ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 3249 - 55
  • CHOWRIRA ET AL., J BIOL. CHEM., vol. 269, 1994, pages 25856
  • KASHANI-SABET ET AL., ANTISENSE RES. DEV., vol. 2, 1992, pages 3 - 15
  • OJWANG ET AL., PROC. NATL ACAD SCI. USA, vol. 89, 1992, pages 10802 - 6
  • YU ET AL., PROC. NATL. ACAD SCI. U S A, vol. 90, 1993, pages 6340 - 4
  • L'HUILLIER ET AL., EMBO J, vol. 11, 1992, pages 4411 - 8
  • LISZIEWICZ ET AL., PROC. NATL. ACAD. SCI. U. S. A, vol. 90, 1993, pages 8000 - 4
  • SULLENGER; CECH, SCIENCE, vol. 262, 1993, pages 1566
  • NOONBERG ET AL., NUCLEIC ACID RES., vol. 22, 1994, pages 2830
  • GOOD ET AL., GENE THER., vol. 4, 1997, pages 45
  • "Remington's Pharmaceutical Science", 1985, MACK PUBLISHING CO.
  • GOODMAN; OILMAN'S: "The Pharmaceutical Basis of Therapeutics", 1990, PERGAMON PRESS
  • SAMBROOK ET AL.: "Molecular Cloning - A Laboratory Manual", 1989, COLD SPRING HARBOR. LABORATORIES
  • AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994, WILEY
  • "PCR Protocols, A Guide to Methods and Amplifications", 1990, ACAD. PRESS

Citation (search report)

  • [X] WO 0149844 A1 20010712 - UNIV RUTGERS [US], et al
  • [A] WO 9740874 A1 19971106 - MEDTRONIC INC [US]
  • [A] WO 0191801 A2 20011206 - CHIRON CORP [US], et al
  • [A] US 6468524 B1 20021022 - CHIORINI JOHN A [US], et al
  • [X] XIA H ET AL: "siRNA-mediated gene silencing in vitro and in vivo", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 10, October 2002 (2002-10-01), pages 1006 - 1010, XP002251054, ISSN: 1087-0156
  • [A] NALDINI L ET AL: "EFFICIENT TRANSFER, INTEGRATION, AND SUSTAINED LONG-TERM EXPRESSIONOF THE TRANSGENE IN ADULT RAT BRAINS INJECTED WITH A LENTIVIRAL VECTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, October 1996 (1996-10-01), pages 11382 - 11388, XP002917173, ISSN: 0027-8424
  • [A] GLORIOSO J C ET AL: "Use of HSV vectors to modify the nervous system", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT 2002 UNITED KINGDOM, vol. 5, no. 2, 2002, pages 289 - 295, XP002278729, ISSN: 1367-6733
  • [A] AEBISCHER P ET AL: "Recombinant proteins for neurodegenerative diseases: the delivery issue", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 9, 1 September 2001 (2001-09-01), pages 533 - 540, XP004298585, ISSN: 0166-2236
  • [A] MCMANUS M T ET AL: "Gene silencing in mammals by small interfering RNAs", NATURE REVIEWS GENETICS, MACMILLAN MAGAZINES, GB, vol. 3, October 2002 (2002-10-01), pages 737 - 747, XP002973403
  • [T] DAVIDSON B L ET AL: "MOLECULAR MEDICINE FOR THE BRAIN: SILENCING OF DISEASE GENES WITH RNA INTERFERENCE", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 3, March 2004 (2004-03-01), pages 145 - 149, XP001180651, ISSN: 1474-4422
  • [T] ISACSON R ET AL: "LACK OF EFFICACY OF 'NAKED' SMALL INTERFERING RNA APPLIED DIRECTLY TO RAT BRAIN", ACTA PHYSIOLOGICA SCANDINAVICA, OXFORD, GB, vol. 179, no. 2, 1 October 2003 (2003-10-01), pages 173 - 177, XP001181130

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004047872 A2 20040610; WO 2004047872 A3 20050203; AT E550025 T1 20120415; AU 2003293035 A1 20040618; AU 2003293035 A8 20040618; CA 2507606 A1 20040610; EP 1569662 A2 20050907; EP 1829547 A2 20070905; EP 1829547 A3 20070912; EP 1832292 A1 20070912; EP 2145628 A1 20100120; EP 2145628 B1 20120321; JP 2006515864 A 20060608; JP 2012006938 A 20120112; JP 4868854 B2 20120201; US 2004162255 A1 20040819; US 2010063134 A1 20100311; US 7605249 B2 20091020; US 8119611 B2 20120221

DOCDB simple family (application)

US 0337650 W 20031126; AT 09013626 T 20031126; AU 2003293035 A 20031126; CA 2507606 A 20031126; EP 03790026 A 20031126; EP 07003774 A 20031126; EP 07003775 A 20031126; EP 09013626 A 20031126; JP 2005510322 A 20031126; JP 2011162422 A 20110725; US 54911009 A 20090827; US 72169303 A 20031125